Abstract
Background: Tangles are deposits of hyperphosphorylated tau, which are found in multiple neurodegenerative disorders that are referred to as tauopathies, of which Alzheimer's disease (AD) is the most common. Tauopathies are clinically characterized by dementia and share common cortical lesions composed of aggregates of the protein tau.
Objective: In this study, we explored the therapeutic potential of tolfenamic acid (TA), in modifying disease processes in a transgenic animal model that carries the human tau gene (hTau).
Methods: Behavioral tests, Western blotting and Immunohistochemical analysis were used to demonstrate the efficacy of TA.
Results: Treatment of TA improved improving spatial learning deficits and memory impairments in young and aged hTau mice. Western blot analysis of the hTau protein revealed reductions in total tau as well as in sitespecific hyperphosphorylation of tau in response to TA administration. Immunohistochemical analysis for phosphorylated tau protein revealed reduced staining in the frontal cortex, hippocampus, and striatum in animals treated with TA.
Conclusion: TA holds the potential as a disease-modifying agent for the treatment of tauopathies including AD.
Keywords: Alzheimer's disease, tolfenamic acid, hTau mouse model, tauopathy, microtubule-associated protein Tau (MAPT), dementia.
Current Alzheimer Research
Title:Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy
Volume: 15 Issue: 7
Author(s): Joanna K. Chang, Allison Leso, Gehad M. Subaiea, Asma Lahouel, Anwar Masoud, Foqia Mushtaq, Reem Deeb, Aseel Eid, Miriam Dash , Syed W. Bihaqi and Nasser H. Zawia*
Affiliation:
- Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI,United States
Keywords: Alzheimer's disease, tolfenamic acid, hTau mouse model, tauopathy, microtubule-associated protein Tau (MAPT), dementia.
Abstract: Background: Tangles are deposits of hyperphosphorylated tau, which are found in multiple neurodegenerative disorders that are referred to as tauopathies, of which Alzheimer's disease (AD) is the most common. Tauopathies are clinically characterized by dementia and share common cortical lesions composed of aggregates of the protein tau.
Objective: In this study, we explored the therapeutic potential of tolfenamic acid (TA), in modifying disease processes in a transgenic animal model that carries the human tau gene (hTau).
Methods: Behavioral tests, Western blotting and Immunohistochemical analysis were used to demonstrate the efficacy of TA.
Results: Treatment of TA improved improving spatial learning deficits and memory impairments in young and aged hTau mice. Western blot analysis of the hTau protein revealed reductions in total tau as well as in sitespecific hyperphosphorylation of tau in response to TA administration. Immunohistochemical analysis for phosphorylated tau protein revealed reduced staining in the frontal cortex, hippocampus, and striatum in animals treated with TA.
Conclusion: TA holds the potential as a disease-modifying agent for the treatment of tauopathies including AD.
Export Options
About this article
Cite this article as:
Chang K. Joanna, Leso Allison, Subaiea M. Gehad, Lahouel Asma, Masoud Anwar, Mushtaq Foqia, Deeb Reem, Eid Aseel, Dash Miriam, Bihaqi W. Syed and Zawia H. Nasser*, Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy, Current Alzheimer Research 2018; 15 (7) . https://dx.doi.org/10.2174/1567205015666180119104036
DOI https://dx.doi.org/10.2174/1567205015666180119104036 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies
The increasing burden of age-related neurodegenerative diseases demands an immediate and pressing need for research in all aspects, from molecular mechanisms to therapeutic interventions. The special issue in Current Alzheimer Research "Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies" aims to highlight the summary of state-of-the-art ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adult Neurogenesis, Neural Stem Cells and Alzheimers Disease: Developments, Limitations, Problems and Promises
Current Alzheimer Research Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Berberine: Pharmacological Features in Health, Disease and Aging
Current Medicinal Chemistry Early-phase 18F-AV-45 PET Imaging can Detect Crossed Cerebellar Diaschisis Following Carotid Artery Stenosis and Cerebral Hypoperfusion
Current Neurovascular Research Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Diabetes Type 4: A Paradigm Shift in the Understanding of Glaucoma, the Brain Specific Diabetes and the Candidature of Insulin as a Therapeutic Agent
Current Molecular Medicine Emerging Nanotechnology for the Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Synthetic Peptides in the Diagnosis of Neurological Diseases
Current Protein & Peptide Science Editorial (Thematic Issue: From Current Diagnostic Tools and Therapeutics for Alzheimer's Disease Towards Earlier Diagnostic Markers and Treatment Targets)
Current Alzheimer Research Shilajit (Mumie): Current Status of Biochemical, Therapeutic and Clinical Advances
Current Nutrition & Food Science Editorial [Hot Topic:Nicotinamide Adenine Dinucleotide Biology and Disease(Executive Editor: W. Todd Penberthy)]
Current Pharmaceutical Design New Technologies for Drug Delivery Across the Blood Brain Barrier
Current Pharmaceutical Design Inflammatory Process in Parkinsons Disease: Role for Cytokines
Current Pharmaceutical Design Molecular Pathways Involved in Apoptotic Cell Death in the Injured Cochlea: Cues to Novel Therapeutic Strategies
Current Pharmaceutical Design When Sick Brain and Hopelessness Meet: Some Aspects of Suicidality in the Neurological Patient
CNS & Neurological Disorders - Drug Targets Pharmacotherapeutic Potential of Garlic in Age-Related Neurological Disorders
CNS & Neurological Disorders - Drug Targets A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery The Renin-Angiotensin System and the Cerebrovascular Diseases: Experimental and Clinical Evidence
Protein & Peptide Letters GuidAge Study: A 5-Year Double Blind, Randomised Trial of EGb 761 for the Prevention of Alzheimers Disease in Elderly Subjects with Memory Complaints. I. Rationale, Design and Baseline Data
Current Alzheimer Research Reduced Alzheimer’s Disease Pathology by St. John’s Wort Treatment is Independent of Hyperforin and Facilitated by ABCC1 and Microglia Activation in Mice
Current Alzheimer Research